M&A Deal Summary |
|
---|---|
Date | 2016-02-22 |
Target | Bristol-Myers - HIV R&D portfolio |
Sector | Life Science |
Buyer(s) | ViiV Healthcare |
Sellers(s) | Bristol-Myers Squibb |
Deal Type | Divestiture |
Deal Value | 350M USD |
SEARCH BY
Try For Free 7-Day Free Trial
ViiV Healthcare is a global specialist HIV company.
DEAL STATS | # |
---|---|
Overall | 1 of 1 |
Sector (Life Science) | 1 of 1 |
Type (Divestiture) | 1 of 1 |
Country (United States) | 1 of 1 |
Year (2016) | 1 of 1 |
Size (of disclosed) | 1 of 1 |
Category | Company |
---|---|
Founded | 1887 |
Sector | Life Science |
Employees | 34,100 |
Revenue | 45.0B USD (2023) |
Bristol-Myers Squibb is a life science company engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. The Company's pharmaceutical products include chemically-synthesized drugs, or small molecules, and an increasing portion of products produced from biological processes. The majority of Bristol-Myers Squibb's revenue comes from products in the following therapeutic classes: cardiovascular; virology, including human immunodeficiency virus (HIV) infection; oncology; neuroscience; immunoscience; and metabolics. Bristol-Myers Squibb was incorporated in 1887 and is based in Princeton, New Jersey.
DEAL STATS | # |
---|---|
Overall | 8 of 13 |
Sector (Life Science) | 2 of 5 |
Type (Divestiture) | 6 of 9 |
Country (United States) | 7 of 8 |
Year (2016) | 1 of 1 |
Size (of disclosed) | 6 of 6 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2015-11-02 |
Cardioxyl Pharmaceuticals
Chapel Hill, North Carolina, United States Cardioxyl Pharmaceuticals, Inc. is a developer of novel therapeutic agents for the treatment of cardiovascular disease. |
Buy | $300M |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2016-03-23 |
Padlock Therapeutics
Cambridge, Massachusetts, United States Padlock Therapeutics, Inc. is a biotechnology company dedicated to creating new medicines to treat destructive autoimmune diseases. |
Buy | $225M |